MARKET

BLUE

BLUE

bluebird bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

60.90
-3.09
-4.83%
Opening 15:55 07/13 EDT
OPEN
64.16
PREV CLOSE
63.99
HIGH
64.52
LOW
60.76
VOLUME
562.00K
TURNOVER
--
52 WEEK HIGH
143.98
52 WEEK LOW
38.95
MARKET CAP
4.02B
P/E (TTM)
-4.0721
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BLUE stock price target is 107.61 with a high estimate of 215.00 and a low estimate of 70.00.

EPS

BLUE News

More
65 Biggest Movers From Yesterday
Gainers MOGU Inc. (NASDAQ: MOGU) shares climbed 104.8% to close at $5.92 on Tuesday.
Benzinga · 5d ago
How Much Of bluebird bio, Inc. (NASDAQ:BLUE) Do Institutions Own?
Simply Wall St. · 6d ago
51 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 6d ago
Wall Street Has Given Up on These 2 Stocks, and That's a Huge Mistake
Motley Fool · 07/01 13:31
2 Top Gene-Editing Stocks to Buy Right Now
MotleyFool.com · 06/28 11:36
Better Buy: Amgen vs. Bristol Myers Squibb
MotleyFool.com · 06/27 04:00
How bluebird bio (BLUE) Stock Stands Out in a Strong Industry
Zacks · 06/23 13:39
Repare and Forma Shares Gobbled Up in IPO
GuruFocus.com · 06/22 21:35

Industry

Biotechnology & Medical Research
-1.87%
Pharmaceuticals & Medical Research
-0.31%

Hot Stocks

Symbol
Price
%Change

About BLUE

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
More

Webull offers kinds of bluebird bio Inc stock information, including NASDAQ:BLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLUE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLUE stock methods without spending real money on the virtual paper trading platform.